Adaptimmune Therapeutics PLC Company Profile (NASDAQ:ADAP)

About Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC logoAdaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADAP
  • CUSIP: N/A
  • Web: www.adaptimmune.com
Capitalization:
  • Market Cap: $497.7 million
  • Outstanding Shares: 93,519,000
Average Prices:
  • 50 Day Moving Avg: $8.18
  • 200 Day Moving Avg: $8.18
  • 52 Week Range: $3.76 - $9.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.89
  • P/E Growth: 0.17
Sales & Book Value:
  • Annual Revenue: $17.33 million
  • Price / Sales: 38.31
  • Book Value: $2.45 per share
  • Price / Book: 2.90
Profitability:
  • EBITDA: ($75,400,000.00)
  • Net Margins: -438.00%
  • Return on Equity: -38.73%
  • Return on Assets: -30.14%
Debt:
  • Current Ratio: 7.86%
  • Quick Ratio: 7.86%
Misc:
  • Average Volume: 364,832 shs.
  • Beta: 1.36
  • Short Ratio: 2.25
 

Frequently Asked Questions for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

What is Adaptimmune Therapeutics PLC's stock symbol?

Adaptimmune Therapeutics PLC trades on the NASDAQ under the ticker symbol "ADAP."

How were Adaptimmune Therapeutics PLC's earnings last quarter?

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.24) EPS for the quarter, meeting the consensus estimate of ($0.24). The business earned $3.52 million during the quarter, compared to analyst estimates of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. View Adaptimmune Therapeutics PLC's Earnings History.

When will Adaptimmune Therapeutics PLC make its next earnings announcement?

Adaptimmune Therapeutics PLC is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Adaptimmune Therapeutics PLC.

Where is Adaptimmune Therapeutics PLC's stock going? Where will Adaptimmune Therapeutics PLC's stock price be in 2017?

5 analysts have issued 1-year target prices for Adaptimmune Therapeutics PLC's stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Adaptimmune Therapeutics PLC's share price to reach $12.50 in the next twelve months. View Analyst Ratings for Adaptimmune Therapeutics PLC.

What are analysts saying about Adaptimmune Therapeutics PLC stock?

Here are some recent quotes from research analysts about Adaptimmune Therapeutics PLC stock:

  • 1. According to Zacks Investment Research, "Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. " (10/4/2017)
  • 2. Cowen and Company analysts commented, "Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells." (6/6/2017)

Are investors shorting Adaptimmune Therapeutics PLC?

Adaptimmune Therapeutics PLC saw a increase in short interest in September. As of September 15th, there was short interest totalling 962,500 shares, an increase of 76.8% from the August 31st total of 544,408 shares. Based on an average trading volume of 636,629 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.2% of the shares of the company are short sold.

Who are some of Adaptimmune Therapeutics PLC's key competitors?

Who are Adaptimmune Therapeutics PLC's key executives?

Adaptimmune Therapeutics PLC's management team includes the folowing people:

  • James Julian Noble, Chief Executive Officer, Director
  • Adrian Rawcliffe, Chief Financial Officer
  • William C. Bertrand Jr. Esq., Chief Operating Officer
  • Gwendolyn Binder-Scholl Ph.D., Chief Technology Officer
  • William Roberts, Vice President of Investor Relations
  • Rafael Amado M.D., Chief Medical Officer
  • Helen Katrina Tayton-Martin Ph.D., Chief Business Officer
  • David M. Mott, Non-Executive Chairman of the Board
  • Lawrence M. Alleva, Non-Executive Independent Director
  • Ali Behbahani M.D., Non-Executive Independent Director

When did Adaptimmune Therapeutics PLC IPO?

(ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Who owns Adaptimmune Therapeutics PLC stock?

Adaptimmune Therapeutics PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include MATRIX CAPITAL MANAGEMENT COMPANY, LP (12.90%). Company insiders that own Adaptimmune Therapeutics PLC stock include Charles Elliott Sigal, Enterprise Associates 14 New and Orbimed Advisors Llc. View Institutional Ownership Trends for Adaptimmune Therapeutics PLC.

How do I buy Adaptimmune Therapeutics PLC stock?

Shares of Adaptimmune Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adaptimmune Therapeutics PLC's stock price today?

One share of Adaptimmune Therapeutics PLC stock can currently be purchased for approximately $7.10.


MarketBeat Community Rating for Adaptimmune Therapeutics PLC (NASDAQ ADAP)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $12.50 (76.06% upside)
Consensus Price Target History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Price Target History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Analysts' Ratings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017SunTrust Banks, Inc.Reiterated RatingBuy$10.00N/AView Rating Details
9/8/2017Leerink SwannReiterated RatingOutperform$15.00LowView Rating Details
6/6/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
3/17/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
10/24/2016Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
9/30/2016Raymond James Financial, Inc.Initiated CoverageOutperform$16.00N/AView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyN/AView Rating Details
2/25/2016Citigroup Inc.Initiated CoverageBuy$15.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Earnings by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Earnings History by Quarter for Adaptimmune Therapeutics PLC (NASDAQ ADAP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017($0.23)N/AView Earnings Details
8/3/20176/30/2017($0.24)($0.24)$5.43 million$3.52 millionViewN/AView Earnings Details
5/10/20173/31/2017($0.24)($0.30)$5.07 million$2.86 millionViewN/AView Earnings Details
3/13/201712/31/2016($0.27)($0.22)$3.98 million$8.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.27)($0.24)($0.26)
Q2 20172($0.26)($0.24)($0.25)
Q3 20172($0.27)($0.25)($0.26)
Q4 20172($0.29)($0.25)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Insider Ownership Percentage: 24.45%
Institutional Ownership Percentage: 68.01%
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Insider Trades by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/27/2017Enterprise Associates 14 NewMajor ShareholderBuy12,870,000$0.70$9,009,000.00View SEC Filing  
3/27/2017Orbimed Advisors LlcDirectorBuy1,190,476$4.20$4,999,999.20View SEC Filing  
5/24/2016Orbimed Advisors LlcDirectorBuy1,712,400$10.42$17,843,208.00View SEC Filing  
5/19/2016Charles Elliott SigalDirectorBuy15,000$1.56$23,400.00View SEC Filing  
5/18/2016Charles Elliott SigalDirectorBuy45,000$1.53$68,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Latest Headlines for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)
Source:
DateHeadline
americanbankingnews.com logo$3.14 Million in Sales Expected for Adaptimmune Therapeutics PLC (ADAP) This Quarter
www.americanbankingnews.com - October 18 at 8:26 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
finance.yahoo.com - October 17 at 3:52 PM
finance.yahoo.com logoImmune Design's Sarcoma Candidate to Enter Phase III in 2018
finance.yahoo.com - October 17 at 3:52 PM
finance.yahoo.com logoShire's New Formulation of Oncaspar Gets CHMP Recommendation
finance.yahoo.com - October 16 at 3:58 PM
finance.yahoo.com logoShire's New Formulation of Oncaspar Gets CHMP Recommendation
finance.yahoo.com - October 16 at 3:58 PM
americanbankingnews.com logo Analysts Anticipate Adaptimmune Therapeutics PLC (ADAP) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - October 16 at 8:20 AM
finance.yahoo.com logoAcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
finance.yahoo.com - October 13 at 3:24 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Receives Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - October 12 at 5:18 PM
finance.yahoo.com logoFlexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up
finance.yahoo.com - October 9 at 4:36 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 7 at 2:38 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 4 at 9:14 PM
seekingalpha.com logoAdaptimmune Therapeutics (ADAP) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology - Slideshow
seekingalpha.com - September 29 at 3:08 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Short Interest Update
www.americanbankingnews.com - September 29 at 2:30 AM
nasdaq.com logoSurging Earnings Estimates Signal Good News for Adaptimmune ... - Nasdaq
www.nasdaq.com - September 23 at 3:37 PM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Adaptimmune Therapeutics (ADAP)
finance.yahoo.com - September 23 at 9:36 AM
finance.yahoo.com logoJames Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
finance.yahoo.com - September 23 at 9:36 AM
americanbankingnews.com logoCritical Contrast: Ritter Pharmaceuticals (RTTR) vs. Adaptimmune Therapeutics PLC (ADAP)
www.americanbankingnews.com - September 17 at 2:50 PM
nasdaq.com logoEuropean ADRs Fractionally Higher as Manufacturers Advance
www.nasdaq.com - September 15 at 3:51 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 12 at 4:48 PM
reuters.com logoBRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics
www.reuters.com - September 12 at 2:06 AM
americanbankingnews.com logo Analysts Anticipate Adaptimmune Therapeutics PLC (ADAP) Will Announce Quarterly Sales of $3.14 Million
www.americanbankingnews.com - September 10 at 3:26 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - September 9 at 12:20 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC's (ADAP) Outperform Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - September 8 at 9:52 PM
reuters.com logoBRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO
www.reuters.com - September 7 at 8:27 PM
streetinsider.com logoGSK Exercising Option Further Validates Adaptimmune (ADAP) TCR Platform - Leerink
www.streetinsider.com - September 7 at 8:27 PM
finance.yahoo.com logoAdaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
finance.yahoo.com - September 6 at 3:25 PM
globenewswire.com logoMersana Appoints Lawrence M. Alleva to Board of Directors Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 1:58 AM
nasdaq.com logoStrength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2% - Nasdaq
www.nasdaq.com - August 31 at 3:23 PM
globenewswire.com logoAdaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker - GlobeNewswire (press release)
globenewswire.com - August 30 at 3:15 PM
finance.yahoo.com logoStrength Seen in Adaptimmune Therapeutics (ADAP): Stock Soars 15.2%
finance.yahoo.com - August 29 at 3:45 PM
thestreet.com logoMore Immunotherapy Buyouts Likely After Kite Sale - TheStreet.com
www.thestreet.com - August 28 at 8:40 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 18 at 5:26 PM
americanbankingnews.com logo$5.43 Million in Sales Expected for Adaptimmune Therapeutics PLC (NASDAQ:ADAP) This Quarter
www.americanbankingnews.com - August 5 at 9:32 AM
globenewswire.com logoAdaptimmune Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:32 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 3 at 4:50 PM
finance.yahoo.com logoAdaptimmune Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 3 at 4:29 PM
finance.yahoo.com logoAdaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
finance.yahoo.com - July 31 at 8:45 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 2:16 PM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Expected to Announce Quarterly Sales of $5.43 Million
www.americanbankingnews.com - July 13 at 9:18 AM
americanbankingnews.com logoAdaptimmune Therapeutics PLC (ADAP) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - July 11 at 8:24 PM
nasdaq.com logoEuropean ADRs Move Higher in Wednesday Trading
www.nasdaq.com - June 14 at 8:21 PM
prnewswire.com logoBioLife Solutions Executes Supply Agreement with Adaptimmune for ... - PR Newswire (press release)
www.prnewswire.com - June 14 at 3:20 PM
reuters.com logoBRIEF-Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
www.reuters.com - June 14 at 8:44 AM
bizjournals.com logoBioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
www.bizjournals.com - June 14 at 8:44 AM
bizjournals.com logoEwing Sarcoma Pipeline Analysis by Stage of Development, Drug Target and Molecule Type New Report Available at RnRMarketResearch.com
www.bizjournals.com - June 13 at 3:20 PM
seekingalpha.com logoAdaptimmune Therapeutics (ADAP) Presents At American Society Of Clinical Oncology 2017 Annual Meeting - Slideshow
seekingalpha.com - June 8 at 8:25 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO ... - StreetInsider.com
www.streetinsider.com - June 6 at 3:32 PM
streetinsider.com logoAdaptimmune Therapeutics (ADAP) Delivers Data from NY-ESO Study in Synovial Sarcoma & Four Trials at ASCO Meetings
www.streetinsider.com - June 5 at 1:28 PM
reuters.com logoBRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
www.reuters.com - June 5 at 1:28 PM
globenewswire.com logoAdaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 28 at 3:18 PM

Social

Chart

Adaptimmune Therapeutics PLC (ADAP) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.